key: cord-0942913-5sr4166x
authors: Are, Chandrakanth; Tyler, D.; Howe, J.; Olivares, A.; Nissan, A.; Zippel, D.; Gupta, A.; Savant, D.; D’Ugo, D.; Rubio, I.; Bargallo-Rocha, J. E.; Martinez-Said, H.; Takeuchi, H.; Taketomi, A.; Oliveira, A. F.; Ribeiro, H. S. Castro; Cheema, M. A.; Majid, H. J.; Chen, G.; Roviello, F.; Gronchi, A.; Leon, A.; Lee, W. Y.; Park, D. J.; Park, J.; Auer, R.; Gawad, W. A.; Zaghloul, A.
title: Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned
date: 2022-02-24
journal: Ann Surg Oncol
DOI: 10.1245/s10434-022-11506-3
sha: 282f3fd4d309b1e5d2720cb39f8d11ac6fa87b2d
doc_id: 942913
cord_uid: 5sr4166x

BACKGROUND: The purpose of this article is to summarize the opinions of the surgical oncology leaders from the Global Forum of Cancer Surgeons (GFCS) about the global impact of COVID-19 pandemic on cancer surgery. METHODS: A panel session (virtual) was held at the annual Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care to address the impact of COVID-19 on cancer surgery globally. Following the virtual meeting, a questionnaire was sent to all the leaders to gather additional opinions. The input obtained from all the leaders was collated and analyzed to understand how cancer surgeons from across the world adapted in real-time to the impact of COVID-19 pandemic. RESULTS: The surgical oncology leaders noted that the COVID-19 pandemic led to severe disruptions in surgical cancer care across all domains of clinical care, education, and research. Several new changes/protocols associated with increased costs were implemented to deliver safe care. Leaders also noted that preexisting disparities in care were exacerbated, and the pandemic had a detrimental effect on well-being and financial status. CONCLUSIONS: The COVID-19 pandemic has led to severe disruptions in surgical cancer care globally. Leaders of the GFCS opined that new strategies need to be implemented to prepare for any future catastrophic events based on the lessons learned from the current events. The GFCS will embark on developing such a roadmap to ensure that surgical cancer care is preserved in the future regardless of any catastrophic global events.

lineage of SARS-CoV-2 virus has led to the emergence of multiple variants, some of which have been more lethal than the original virus. 3 It is likely that SARS-CoV-2 virus and its evolutionary variants will continue to add to the incrementally accumulating burden of this disease.

The COVID-19 pandemic has had a grave impact on every facet of life with catastrophic consequences for the entire world. 1 The brunt of this impact has been felt the most in the field of health care with interruptions in care delivery and adverse consequences to both patients and caregivers. [4] [5] [6] The World Health Organization (WHO) conducted a rapid assessment survey of service delivery for noncommunicable diseases during the first wave of the pandemic in 2020. 4 The survey was conducted between May 1-25, 2020 and involved 194 Ministries of Health across the world. Nearly 122 countries reported that they noted disruptions in services for many noncommunicable diseases. Disruptions (partial or complete) in cancer delivery services were reported by approximately 42% of the responding countries. Approximately 5% of the countries noted complete interruptions.

Riera et al. conducted a systematic review of studies to specifically identify, categorize, and estimate the frequency of delays and disruptions in global cancer health care due to the COVID-19 pandemic. 5 Despite lacking high methodological quality, the included 62 studies identified multiple and severe disruptions along the entire chain of cancer care delivery. Treatment delays (26-62.4%), treatment interruption (77.5%), change in treatment plan (1.6-82%), and reduction in cancer treatment (42%) were noted by the authors. Specific to surgical care, treatment delay (3.34-76%), treatment interruption (30-80%), and reduction of the number of surgeries (14.28-85.8%) were documented across the world.

The impact of COVID-19 on cancer with a specific focus on surgical care was analyzed by the COVIDSurg Collaborative. 6 This international, prospective, cohort study was conducted in 2020 by obtaining data from 466 hospitals in 61 countries across the world. The authors sought to analyze the impact of COVID-19 on disruptions in surgical cancer care for 15 solid organ cancer types and included 20,006 patients. Of all the eligible patients, nearly 10% of the patients did not receive surgery after a median follow-up of 23 weeks. The level of interruptions in cancer surgical care varied based on several factors, such as the stringency of lockdowns (low, medium, and high) and income status (based on World Bank Index: high-income countries, upper middle-income countries, and low-tomiddle-income countries) of the respective countries.

The Global Forum of Cancer Surgeons (GFCS) was formed in 2017 to advance the goals of cancer surgery on the global stage. 7, 8 The mission of the GFCS is to provide a voice for cancer surgeons to improve surgical care for cancer patients through multidisciplinary clinical care, education, research, outreach advocacy, and leadership on the global stage. 9 The GFCS consists of surgical oncology leaders from 15 reputable surgical oncology societies across the world. These societies with their respective leaders represent more than 75% of the global cancer burden by incidence and mortality.

The GFCS, in its nascent stages, has strived to advocate for cancer surgery on the global stage through several initiatives. Some of the initiatives include addressing the barriers to cancer surgery 10 and promoting the benefits 11 of safe and timely cancer surgery. The GFCS also has been involved in addressing specific issues relating to cancer surgery in specific countries. One such initiative included collaboration with the Brazilian Society of Surgical Oncology (BSSO) and other bodies to successfully lobby the Brazilian government to include cytoreductive surgery/hyperthermic intraperitoneal chemotherapy in the Brazilian Public Health System (Sistema Ú nico de Saúde, or SUS). 12 As expected, the emergence of SARS-CoV-2 virus prompted the leaders of the GFCS to discuss the adverse ramifications of the COVID-19 pandemic on cancer surgery globally. The purpose of this article is to summarize the opinions of the surgical oncology leaders of the GFCS about the impact of the COVID-19 pandemic on cancer surgery on the global stage.

A panel session (virtual) was held at the annual Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care to address the impact of COVID-19 on the global stage. This session (Cancer Surgery During a Pandemic: A Global Perspective) sought to obtain the opinions of global cancer surgery leaders about the impact of COVID-19 on the various domains of cancer surgical care. Following the virtual meeting, a questionnaire was sent to all the leaders to gather additional opinions regarding the impact of the COVID-19 pandemic on cancer surgery. Opinions were sought on the various domains of cancer surgical care ranging from: clinical care, education, research, well-being, effect of inequities, impact on financial situation, etc. The input obtained from all the leaders was collated and analyzed to understand how cancer surgeons from across the world adapted to the impact of the COVID-19 pandemic.

Findings about interruptions in cancer surgery (canceled elective cancer surgery) and cancers most affected are documented in Table 1 . The majority of the leaders (76%) noted that elective cancer surgical cases were canceled as a result of the pandemic. The most common time period for cancellation of elective cancer surgical cases was during the first half of 2020. Leaders from Israel, Italy, and Republic of Korea did not document cancellation of elective cancer surgical cases. Although nearly all cancer sites were affected, the most common cancers affected by the pandemic were related to breast, colorectal, thyroid, and gastrointestinal cancers. Despite not cancelling elective cancer surgical cases, leaders from Israel, Italy, and Republic of Korea noted an adverse impact on cancer care related to breast, colorectal, gastrointestinal, and other malignancies.

Changes/new protocols implemented in the perioperative setting to accommodate for the COVID-19 pandemic are documented in Table 2 . The common adaptive themes that emerged from the preoperative setting included: enhanced screening for COVID-19 with near universal use of RT-PCR testing and other investigations, reducing surgical procedures (particularly complex procedures) or shifting to an ambulatory setting where feasible, minimizing procedures that may need stay in the Intensive Care Unit (ICU), triaging patients for procedures, categorizing risk status for potential COVID-19 infection, and restrictive visitor policies.

In the intraoperative setting, the most common changes consisted of: use of Personal Protective Equipment (PPE) and following universal precautions, avoiding or modifying laparoscopic procedures to minimize aerosolization, avoiding or minimizing other aerosol-generating procedures, special precautions during intubation and extubation, minimizing the number of personnel in the operating room (OR), dedicating particular ORs for patients with COVID-19, and modifications to other OR equipment (electrocautery, suction, etc.).

In the postoperative setting, the changes and new policies focused on: early discharge, implementation of Early Recovery After Surgery (ERAS) protocols, restrictive visitor policies, continued vigilance with retesting for COVID-19 patients as needed, and modifying nursing care patterns to minimize visitors.

The majority of the respondents noted that they faced shortages of PPE to varying degrees (mild to severe, requiring adaptation in some cases by using raincoats under surgical gowns, etc.) during the early stages of the pandemic. Over the course of 2020 and later, nearly all reached sufficiency with PPE from a combination of enhanced local production or importing from other countries.

The majority of leaders noted that the disruptions to surgical cancer care due to the pandemic will affect the long-term prognosis at the individual and population level. This is due to multiple factors ranging from: reducing screening for cancer, such as breast/colorectal, etc., lack of screening leading to presentation of cancers at more advanced stages of disease, delayed or cancelled surgical procedures, and inability to offer other treatment options when surgery is cancelled. Many respondents noted that they are already witnessing an increase in the numbers of patients with advanced stages of disease. Leaders from places where surgical care was resumed quickly felt that the impact on long-term prognosis may be minimal.

The majority of respondents noted a significant negative impact on surgical research due to various factors: preferential allocation of all resources to address the COVID-19 pandemic and inability to or slowdown of recruitment of patients into trials due to lack of or reduced patient contact (Table 3) . Some noted that established trials were allowed to continue with or without modifications, albeit at a slower pace with a pause on initiation of new trials. Paradoxically, some responded that they found more time to conduct research not requiring direct clinical input. Although there was a reduction in the overall level of research activity, the majority noted that they initiated new research protocols or trials related to the impact of COVID-19 on cancer care.

Similarly, the majority of respondents expressed a concern of the significant impact on surgical education. For many of the countries/regions, education was transitioned to virtual formats. Education in the OR was significantly disrupted due to the precautionary reduction in the number of personnel permitted, which by hierarchical default affected trainees the most. Some countries felt the need to arrange dedicated workshops to make up for the loss of months of surgical skill training. Although the impact on education was felt to be significant, many noted that they were able to return to pre-pandemic educational routines within a few months.

The impact on ancillary domains of cancer care during the COVID-19 pandemic is documented in Table 4 . Not surprisingly, patients from the lower socio-economic strata (LSES) in some countries were affected the most due to delays in screening and care. LSES patients traditionally access the public health systems which were hit harder in these aforesaid countries. As of result of the heightened impact on the public health care systems, some noted a worsening of the preexisting disparities in cancer care for LSES patients. Some countries did not notice any detrimental effect, which was particularly noted in countries that had any type of preexisting robust National Health Service/System (NHS) in place for health care delivery. Many countries/regions noted a significant financial impact related to loss of revenue combined with an increase in costs to deliver care in the COVID-19 environment. In some countries, governmental aid was instrumental in compensating for the financial losses resulting in a net neutral situation. Some other countries acknowledged the significant financial effects but the full impact is yet to be determined.

The COVID-19 pandemic had a significant impact on the morale and well-being of the surgical community due to many reasons, such as: fear of the unknown, unpredictable work patterns, reduced remuneration, inability to travel and interact with peers, and social isolation. Several respondents noted that they proactively implemented measures to improve well-being and morale, such as: increasing support through professional societies, increasing online interactions and social media activities, providing counseling (online and in-person) services, maintaining normalcy as much as possible, and providing adequate time off.

Lessons Learned and Strategies for the Future are Documented in Table 5 Some of the respondents noted that cancellation of cancer surgical procedures must be avoided at any cost. This would obviously depend on the presence of prior care platforms that help to plan, anticipate, and implement alternative treatment pathways when forced to cancel planned elective cancer operations. The role and importance of multidisciplinary teams in determining alternative treatment strategies also was highlighted as was the collaborative spirit between surgical, medical, and radiation oncologists. Several respondents felt that they found new appreciation for the resilience displayed by cancer professionals even under the duress of a pandemic. Some respondents emphasized other lessons, such as: improving efficiency in screening, developing triage algorithms, exploiting the value of ambulatory care platforms, promoting virtual platforms for patient care and education, obtaining real-time data on COVID-19 burden, and the value of assisted funding from government to help cope with the pandemic.

Several strategies were suggested to help prepare for any future catastrophic events. Creating dedicated units/ 

The primary and specific goal of this article is to summarize the opinions from the leaders of the GFCS about the impact of COVID-19 pandemic on cancer surgery. The leaders of the GFCS hail from different parts of the world and represent nearly three-quarters of the global cancer burden by incidence and mortality.

The members of GFCS also hold leadership positions in the respective surgical oncology societies of their country/region. Through these leadership positions, they tend to be involved in steering and guiding the educational paradigms, research platforms, and delivery of cancer surgery in their respective geographic region/s. As a result, the opinions of these leaders on matters related to cancer surgery tend to be strategic, visionary, pragmatic, broadly applicable in scope, and extremely valuable.

It is not surprising that the leaders felt that the pandemic had a devastating effect on nearly every aspect extending from clinical care, education, and research with equally detrimental effects on well-being and financial status. Clinical care was noted to be severely compromised with delayed or canceled elective procedures due to various reasons, such as diversion of efforts to address COVID-19, lack of PPE, unpredictability of workflows, and lack of screening amongst several other factors. It is ironical to note that cancers with well-established screening strategies (breast, colorectal) were affected the most. Many felt that this degree of disruption in cancer care will have a negative prognostic impact in the long-term and may contribute to a new phenomenon of stage migration. 13 Severe interruptions also were noted in delivery of education and conduct of research. The increased costs associated with delivering care under new/extra precautions combined with lost revenue resulting from fewer surgical procedures had a major financial impact on individual surgeons as well as hospitals. The fear of uncertainty, extremely unpredictable work schedules, social isolation, and inability to interact with peers on a regular basis adversely impacted the well-being of surgeons as well as every other health profession.

Despite the persistent duress of the pandemic for a prolonged period, there were some redeeming aspects highlighted as well. Many appreciated the hitherto underappreciated, dynamism, adaptability, and resilience of the surgical oncology community and witnessed the true spirit of collaboration with our colleagues in medical and radiation oncology. Although research overall was severely compromised, this pandemic provided a new opportunity for research related to COVID-19 and cancer surgery, which may be beneficial for any future catastrophic events. The additional funding provided by the respective governments served as lifelines during the pandemic. The pandemic also highlighted the benefits of collaboration between individuals and surgical oncology societies across the world to cross-pollinate the best and worst practices.

There are several limitations to this paper. It is based exclusively on the opinions of surgical oncologists rather than on any prospective or retrospective study design. Although the members of the GFCS hold leadership roles, it is likely that their opinions may not represent the views, outcomes, and practices of the entirety of the country or region they represent. Similarly, it is not clear why some cancers were affected more than others. It could be a reflection of various factors, such as the availability of specific resources, complexity of treatment required, availability of adjuvant options, and aggressive or indolent nature of each specific cancer.

It was felt by everyone at the virtual meeting that we need to develop strategies to guide the global surgical oncology community. These strategies will be extremely helpful to guide cancer surgeons, hospitals, policy makers, and governments across the world to deliver uninterrupted surgical care for cancer patients in the event of another catastrophic event in the future. The Global Forum of Cancer Surgeons is well suited for this purpose and will embark on this as its next initiative. DISCLOSURE Douglas Tyler: up to date royalties for writing section, Castle Bioscience Honorarium for participation in scientific advisory board $1500 11/22/20.

(cleared)_125bf384-9333-40c9-aab2-c0ecafb76ab2.pdf?sfvrsn=6296324c_20. Accessed

Delays and disruptions in cancer health care due to COVID-19 pandemic: Systematic review

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries: an international, prospective, cohort study

Global forum of cancer surgeons: declaration of intent

Global Forum of Cancer Surgeons: a steady voice for cancer surgeons to improve surgical care for cancer patients globally

Global Forum of Cancer Surgeons: perspectives on barriers to surgical care for cancer patients and potential solutions

Global Forum of Cancer Surgeons: position statement to promote cancer surgery globally

Global forum of cancer surgeons: support for the brazilian society of surgical oncology journey towards implementation of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy in Brazil

COVID-19 stage migration (CSM): a new phenomenon in oncology